Experiencia de 10 años en el tratamiento con epoprostenol en perfusión intravenosa continua en hipertensión pulmonar arterial grave

Bibliografía

1. Fuster V, Giuliani ER, Brandemburg RO, Weidman WH, Edwards WD.. The natural history of idiopathic pulmonary hypertension. Am J Cardiol 1981;47:422.
2. Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al.. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991;115:343.
3. Jones DK, Higgenbottam TW, Wallwork J.. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J 1987;57:270-8.
4. Conte JV, Gaine SP, Orens JB, Harris T, Rubin LJ.. The influence of continuous prostacyclin therapy for primary pumonary hypertension on the timing and outcome of transplantation. J Heart Lung Trasplant 1998;17:679-85.
5. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS.. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121: 409-15.
6. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al.. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
7. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, et al.. Primary pulmonary hypertension: improved long-term effects and survival with continous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-9.
8. Humbert M, Sánchez O, Fartoukh M, Jagot JL, Sitbon O, Simmoneau G.. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous iv epoprostenol (prostacyclin). Chest 1998;114:80S-2S.
9. Hernández P, Gómez-Sánchez MA, Lázaro M, Tello R, Escribano P, Hernández F, et al.. Hipertensión Pulmonar Primaria: tratamiento a largo plazo con amlodipino [abstract]. Rev Esp Cardiol 2001;54 (Supl 2):118
10. Gómez-Sánchez MA, Sáenz de la Calzada C, Gómez Pajuelo C, Martínez Tello FJ, Mestre de Juan MJ, James TN.. Clinical and pathologic manifestation of pulmonary vascular disease in the toxic oil syndrome. J Am Coll Cardiol 1991;18;1539-5.
11. Badesch D, Tapson V, McGoon M, Brundage B, Rubin L, Wigley F, et al.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum disease. Ann Intern Med 2000;132:425-34.
12. Aguilar R, Farber H.. Epoprostenol (prostacyclin) therapy in HIV associated pulmonary hypertension. Am J Respir Crit Care Med 2000;162:1846-50.
13. Martínez Torres MA, Pavón Jiménez R, Corzo Delgado J, Pastor Torres L.. Hipertensión pulmonar asociada a infección por VIH: revisión de 4 casos. Rev Esp Cardiol 2002;55:673-7.
14. Rubin LJ, Mendoza J, Hood M, McGoon MD, Barst RJ, William W, et al.. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann Intern Med 1990;112:485-91.
15. Wax D, Garofano R, Barst RJ.. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 1999;116:914-20.
16. Robbins IM, Christman BW, Newman JH, Matlock R, Loyd JE.. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 1998; 114:1269-75.
17. Hinderliter AL, Willis PW, Barst RJ, Rich S, Rubin LJ, Badesch DB, et al.. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-86.
18. British Cardiac Society Guidelines and Medical Practice Committee.. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001;86(Suppl I):i1-i13.
19. McLaughlin VV, Genthner DE, Panella MM, Rich S.. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
20. Higgenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L.. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998;80:151-5.
21. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al.. Long term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-70.
22. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoper M.. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH study group. Ann Intern Med 2000;132:435-43.
23. Simonneau G, Barst R, Galie N, Naeije R, Rich S, Bourge RC, et al.. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:800-4.
24. Rich S, Kauffmann E, Levy PS.. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
25. Rich S, Brundage BH.. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.
26. Sáenz de la Calzada C, Sánchez V, Velásquez MT, Tello R, Gómez-Sánchez MA, Delgado J, et al.. Guías de práctica clínica de la Sociedad Española de Cardiología en tromboembolismo e hipertensión pulmonar. Rev Esp Cardiol 2001;54:194-210.